Day: January 18, 2019

Bleeding and Clotting Disorders

Protocol:ALN-AT3SC-004

Condition or Disease: Hemophilia A or B

Study Type: Interventional (Clinical Trial)

Status: Open for enrollment

Study Title: ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX

Principal I investigator: Joseph Lasky III, MD

More Info: //clinicaltrials.gov/ct2/show/NCT03417245

Bleeding and Clotting Disorders

Protocol:1160.106

Condition or Disease: Venous thrombosis

Study Type: Interventional (Clinical Trial)

Status: Open for enrollment

Study Title: Open-label, randomized, parallel-group, active-controlled, multi-centre, non-inferiority study of dabigatran etexilate versus standard of care for venous thromboembolism treatment in children from birth to less than 18 years of age: The DIVERSITY study

Principal I investigator: Alan Ikeda, MD

More Info: //clinicaltrials.gov/ct2/show/NCT01895777

Bleeding and Clotting Disorders

Protocol:1160.108

Condition or Disease: Venous Thromboembolism, Secondary Prevention

Study Type: Interventional (Clinical Trial)

Status: Open for enrollment

Study Title: Open label, single arm safety prospective cohort study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years

Principal I investigator: Alan Ikeda, MD

More Info: //clinicaltrials.gov/ct2/show/NCT02197416

Bleeding and Clotting Disorders

Protocol:1321.7

Condition or Disease: Hemorrhage

Study Type: Interventional (Clinical Trial)

Status: Open for enrollment

Study Title: Single dose, open label, uncontrolled, safety trial of intravenous administration of idarucizumab to paediatric patients enrolled from ongoing phase IIb/III clinical trials with dabigatran etexilate for the treatment and secondary prevention of venous thromboembolism.

Principal I investigator: Alan Ikeda, MD

More Info: //clinicaltrials.gov/ct2/show/NCT02815670